Skip to Content

02. July 2009

Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion

Roche announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to branch retinal vein occlusion. more

Services

Upcoming Events